Know Cancer

or
forgot password

[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer


N/A
21 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer


Our long-range objective is to obtain pilot data to investigate the ability of the new
dual-modality positron emission tomography and computed tomography (PET-CT) imaging systems
for assessing treatment response in patients with metastatic prostate cancer in comparison
to conventional imaging. PET-CT is not employed here for staging; all men in this study will
have stage IV metastatic prostate cancer. We believe that the combined anatomic and in-vivo
metabolic imaging information provided by PET-CT allows accurate objective assessment of
such critical clinical issues as early prediction and evaluation of response or resistance
to various therapeutic interventions, including the novel chemotherapy regimen, as well as
the prediction of key clinical outcomes such as time to hormone-refractoriness and survival.
Our intermediate-range objective is therefore to investigate the diagnostic and prognostic
utility of PET-CT with the most commonly available PET tracer, [F-18]-fluorodeoxyglucose
(FDG), in metastatic prostate cancer. We plan to correlate the treatment-induced changes of
glucose metabolism in metastatic prostate cancer lesions to the changes in various
conventional clinical, laboratory, and diagnostic imaging parameters such as serum
prostate-specific antigen level, lesion size, time to androgen independence, and survival.
This objective is motivated by our preliminary basic science and clinical data as well as
the published reports of other investigators demonstrating the pragmatic potential
diagnostic and prognostic utility of FDG PET-CT in men with metastatic prostate cancer.


Inclusion Criteria:



Group-I (hormone-responsive) inclusion criteria:

- Age > 21 years, men of all ethnic backgrounds

- Patient must have had a histological diagnosis of adenocarcinoma of prostate and
currently must have metastatic disease (stage TxNxM1) that is hormone- naïve received
prior to the development of objective evidence for MACRO metastatic or recurrent
disease (e.g. during biochemical PSA relapse without imaging evidence of disease).

- Evidence of metastatic disease must be documented as: conventional imaging evidence
for metastatic disease as determined by CT, bone scintigraphy, or both (Note:
although there are no strict windows for obtaining other scans bone, CT) relative to
the timing of the PET scans, every effort will be made to have these 'standard' scans
obtained within 3 months of the Baseline PET scan

Group-II (hormone-refractory) inclusion criteria:

- Age > 21 years, men of all ethnic backgrounds

- Patients must have received prior hormonal therapy. Patients treated with orchiectomy
are eligible.

- Patient must have had a histological diagnosis of adenocarcinoma of prostate and
currently must have metastatic disease (stage TxNxM1) that is unresponsive or
refractory to hormonal therapy. Evidence of unresponsive or refractory disease must
be documented by either:

1. a progression of disease assessed with CT or bone scan or as judged clinically
based on factors such as increasing bone pain (Note: although there are no
strict windows for obtaining other scans (bone, CT) relative to the timing of
the PET scans, every effort will be made to have these 'standard' scans obtained
within 3 months of the PET scan) OR

2. a rising serum PSA level - defined as at least 2 consecutive rises in PSA
documented over a reference value (1st measure within 3 months prior to
recruitment); The first rising PSA (2nd measure) should be taken at least 14
days after the reference value. A confirmatory PSA measure (3rd measure) should
be obtained at least 14 days after the 2nd measure and must be greater than the
2nd measure. Additionally, patient must have a serum PSA concentration of at
least 2 ng/mL in addition to increasing PSA to be eligible. However, if the
patient is clinically judged to have progressive disease irrespective of PSA
(e.g. metastasis-related bone pain, clear increase in lesions evident on a bone
scan and/or CT if available), documenting a minimum or rising PSA level would
not be required.

Other general inclusion criteria for both groups:

- If the treating physician has determined that the patient is not clinically
responding to the current therapy prescribed and, in the best interest of the
patient, the physician plans to change the treatment to a new treatment.

1. Example: a Group I patient currently treated with a form of anti-androgen
therapy which is not responding; the patient can be considered for enrollment
into the PET-CT imaging study prior to a new anti-androgen therapy even though
he was treated with anti-androgen therapy before. The wait time between the end
of old therapy and the beginning of the new therapy is based entirely on
clinical judgment

2. Example: a Group II patient currently treated with a form of therapy for hormone
refractory disease (chemo) therapy which is not responding; the patient can be
considered for enrollment into the PET-CT imaging study prior to a new therapy
even though he was treated with chemotherapy another type of hormone-refractive
therapy before. The wait time between the end of old therapy and the beginning
of the new therapy is based entirely on clinical judgment

- May have received prior surgery (14 days must have elapsed since completion of
surgery with recovery from side effects)

- Creatinine ≤ 2.5 x the institutional upper limit of normal (within 28 days prior to
enrollment)

- Men of childbearing potential must be willing to consent to use effective
contraception.

- Must be competent to consent to study requirements

- Patients may also be enrolled in the study from either group if the therapeutic
regimen (hormone therapy or chemotherapy and/or other therapies for hormone
refractory disease has been administered for up to 2 weeks prior to the baseline PET
scan.

- OPTIONAL: Completed analgesic pain survey. If unable to complete questionnaires in
English or Spanish, patient can still participate in this study.

Exclusion Criteria:

- History of cancer other than prostate cancer (except squamous cell carcinoma of the
skin that has been treated with curative intent) or other cancers clinically judged
to be cured or inactive based on history, physical examination, tumor markers, or
imaging findings.

- Active infection (except mild upper respiratory infections or other sites if
clinically judged not to interfere with image interpretation on a per case basis)

- History of poorly-controlled diabetes mellitus (with Fasting Blood Glucose greater
than 200 mg/dL) - in order to avoid false negative results due to glucose
competition with [F-18]-Fluorodeoxyglucose in cellular uptake

- Active inflammatory conditions (e.g. rheumatoid arthritis, sarcoid)

- History of complicated non-healing fracture

- Not competent to consent

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

PET/CT imaging validity

Outcome Time Frame:

every 4 months

Safety Issue:

No

Principal Investigator

Hossein Jadvar, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

USC/Norris Comprehensive Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

4P-05-1

NCT ID:

NCT00282906

Start Date:

October 2005

Completion Date:

June 2014

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location

USC/Norris Comprehensive Cancer CenterLos Angeles, California  90033-0800